Australian Pharmaceutical Industries Limited (ASX: API) has released its investor presentation where it has provided API’s activities current at the date of the presentation.
In the presentation, the company discussed about its strategies and is confident of the right capability to implement. The leadership of API is focussed on growth opportunities like:
- Pipeline of Priceline Pharmacies & Clear Skincare clinics.
- Consumer Brands sales growth from 2HFY2020.
- Pharmacy Distribution upside from AstraZeneca & Upjohn.
The company has a stringent balance sheet management and strong cash generation. New Sydney DC investment was of $50 million to offer a leading-edge distribution capability.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.